InnovAge (NASDAQ:INNV) Price Target Raised to $14.00 at KeyCorp

Posted by on Sep 9th, 2026

InnovAge (NASDAQ:INNV – Get Free Report) had its price target lifted by KeyCorp from $13.00 to $14.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. KeyCorp’s price target indicates a potential upside of 33.08% from the company’s previous close.

Several other equities research analysts have also issued reports on the stock. Wall Street Zen lowered shares of InnovAge from a “buy” rating to a “hold” rating in a report on Sunday, May 17th. Weiss Ratings restated a “sell (d-)” rating on shares of InnovAge in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $10.50.

View Our Latest Analysis on InnovAge

InnovAge Stock Performance

NASDAQ INNV opened at $10.52 on Wednesday. The business’s 50 day moving average price is $11.20 and its 200-day moving average price is $9.32. InnovAge has a fifty-two week low of $3.82 and a fifty-two week high of $12.64. The company has a market cap of $1.43 billion, a P/E ratio of -116.89 and a beta of 0.40. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.03 and a current ratio of 1.03.

InnovAge (NASDAQ:INNV – Get Free Report) last issued its quarterly earnings results on Tuesday, September 8th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The company had revenue of $261.95 million during the quarter, compared to the consensus estimate of $238.33 million. InnovAge had a negative return on equity of 4.73% and a negative net margin of 1.22%.

Institutional Investors Weigh In On InnovAge

A number of institutional investors and hedge funds have recently bought and sold shares of INNV. T. Rowe Price Investment Management Inc. grew its position in shares of InnovAge by 10.3% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,168,330 shares of the company’s stock worth $32,014,000 after buying an additional 577,558 shares in the last quarter. Kent Lake PR LLC increased its position in InnovAge by 13.1% during the 2nd quarter. Kent Lake PR LLC now owns 1,697,036 shares of the company’s stock valued at $6,262,000 after purchasing an additional 197,036 shares during the period. BlackRock Inc. bought a new stake in shares of InnovAge in the 2nd quarter valued at about $17,652,000. Vanguard Group Inc. raised its holdings in shares of InnovAge by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,124,321 shares of the company’s stock valued at $5,801,000 after purchasing an additional 4,239 shares in the last quarter. Finally, Algert Global LLC lifted its position in shares of InnovAge by 844.1% in the 2nd quarter. Algert Global LLC now owns 630,520 shares of the company’s stock worth $7,472,000 after purchasing an additional 563,735 shares during the period. 12.26% of the stock is owned by institutional investors.

Key Headlines Impacting InnovAge

Here are the key news stories impacting InnovAge this week:

  • Positive Sentiment: InnovAge forecast fiscal 2027 revenue of approximately $1.05 billion to $1.085 billion and adjusted EBITDA of $105 million to $115 million. The company also expects census growth of 5% to 7.5%, signaling continued expansion of its senior-care business. Fiscal 2027 guidance
  • Positive Sentiment: Fiscal fourth-quarter revenue reached $261.95 million, exceeding the analyst estimate of $238.33 million. The revenue beat suggests solid operating momentum despite profitability challenges. InnovAge quarterly results
  • Neutral Sentiment: Management highlighted growth milestones and a stronger operational foundation as it begins a new phase of expansion. Investors will likely focus on whether the company can convert that growth into consistent profitability. InnovAge growth milestones
  • Negative Sentiment: InnovAge reported fiscal fourth-quarter EPS of $0.06, below estimates ranging from $0.07 to $0.09. The company also posted a negative net margin and negative return on equity, underscoring ongoing profitability risks. InnovAge EPS miss

About InnovAge

(Get Free Report)

InnovAge Holdings, Inc (NASDAQ:INNV) is a healthcare services company that specializes in caring for seniors through the Program of All-Inclusive Care for the Elderly (PACE). Designed for individuals who are eligible for both Medicare and Medicaid, the PACE model integrates medical care, social services and long-term care—delivered primarily in participants’ homes and community-based centers. InnovAge’s approach centers on interdisciplinary care teams that coordinate everything from primary and specialty medical services to nutritional counseling and recreational activities.

The company’s core offerings include comprehensive in-home assessments, physician and nursing services, physical and occupational therapy, prescription medication management, and transportation to medical appointments.

Read More

Receive News & Ratings for InnovAge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnovAge and related companies with MarketBeat.com's FREE daily email newsletter.